Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer

ConclusionsOur findings suggest that177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node metastatic castration-resistant prostate cancer, and in individuals with chemotherapy-na ïve status and lower levels of baseline PSA.

http://link.springer.com/10.1007/s11523-021-00801-w

Source: Targeted Oncology - March 9, 2021 Category: Cancer & Oncology Source Type: research